Related Experiment Video
Updated: Feb 9, 2026

Mouse Sperm Cryopreservation and Recovery using the I·Cryo Kit
Published on: December 12, 2011
Apatinib treatment for KIT- and KDR-amplified angiosarcoma: a case report
Lishu Yang1, Lizhu Liu1, Bo Han2
1Department of Oncology, First Affiliated Hospital of Harbin Medical University, Harbin, 150001, China.
Background:
Metastatic or relapsed angiosarcoma has a poor prognosis and the efficacy of conventional chemotherapy is often limited. Apatinib, a novel tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptor-2 (VEGFR2), has been approved for the treatment of advanced gastric cancer.
Case Presentation:
Herein, we report a patient with advanced angiosarcoma, who received apatinib at a daily dose of 250 to 725 mg, resulting in a partial response for three months, which may be related to Kinase Insert Domain Receptor (KDR) gene amplification.
Conclusion:
Our experience reported here indicated that apatinib may be a useful therapeutic option for treatment of patients with advanced angiosarcoma.
Related Concept Videos
Operational Amplifiers
MOSFET Amplifiers
BJT Amplifiers
In BJT amplifier configurations, particularly in common-emitter setups, the transistor's role...
Instrumentation Amplifier
To overcome this challenge, an ECG machine utilizes an instrumentation amplifier. This specialized amplifier is...
Amplifying Signals via Second Messengers
Amplifying Signals via Enzymatic Cascade

